Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor

被引:5
作者
Ge, Lisheng
Zhang, Jian Gang [2 ]
Samathanam, Christina A. [2 ]
Delgado, Christina
Tarbiyat-Boldaji, Mary
Dan, Qinghong [2 ]
Hoa, Neil
Nguyen, Tuong-Vi
Alipanah, Reza
Pham, Jimmy T. H.
Sanchez, Ramon
Wepsic, H. Terry [2 ]
Morgan, Timothy R. [3 ,4 ]
Jadus, Martin R. [1 ,2 ,5 ]
机构
[1] VA Long Beach Healthcare Syst, Pathol & Lab Med Serv, Diagnost & Mol Med Hlth Care Grp, Dept Lab Serv, Long Beach, CA 90822 USA
[2] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92117 USA
[3] Univ Calif Irvine, Dept Gastroenterol, Irvine, CA 92117 USA
[4] VA Long Beach Healthcare Syst, Med Hlth Care Grp, Long Beach, CA 90822 USA
[5] Univ Calif Irvine, Neurooncol Program, Chao Comprehens Canc Ctr, Orange, CA 92868 USA
关键词
Hepatocellular carcinoma; Macrophage colony stimulating factor; Alt-macrophage colony stimulating factor; Cytotoxic T lymphocytes; Hepa1-6; HepG2; RMA-S; Tumor immunity; Autoimmunity; PULSED DENDRITIC CELLS; ALPHA-FETOPROTEIN; TRANSFORMING GROWTH-FACTOR-BETA-1; CYTOLYTIC ACTIVITY; ANTIGENIC PEPTIDE; PERIPHERAL-BLOOD; VIRUS-INFECTION; HEPATOMA-CELLS; POOR-PROGNOSIS; TUMOR VACCINE;
D O I
10.1016/j.cellimm.2009.06.008
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mouse Hepa1-6 hepatocellular carcinoma (HCC) cells were transduced with the membrane form of macrophage colony stimulating factor (mM-CSF). When mM-CSF transduced Hepa1-6 cells were injected subcutaneously into mice, these cells did not form tumors. The spleens of these immunized mice contained cytotoxic CD8(+) T lymphocytes (CTL) that killed the unmodified Hepa1-6 cells. We show that the alternative form of macrophage colony stimulating factor (altM-CSF) induced CTL-mediated immunity against Hepa1-6 cells. AltM-CSF is restricted to the H-2D(b) allele. CTLs killed RMA-S cells loaded with exogenous altM-CSF peptide. Vaccination of mice with dendritic cells pulsed with the altM-CSF peptide stimulated anti-Hepa1-6 CTLs. Hyper-immunization of mice with mM-CSF Hepa1-6 cells showed inflammation of the liver and kidneys. Although altM-CSF was expressed within liver and kidney cells, its intensity was lower than Hepa1-6 cells. AltM-CSF was detected within the human HepG2 cell line. These studies suggest that altM-CSF may be a tumor antigen for HCC. Published by Elsevier Inc.
引用
收藏
页码:117 / 127
页数:11
相关论文
共 55 条
  • [1] Andersen MH, 2001, CANCER RES, V61, P869
  • [2] Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma
    Bricard, G
    Bouzourene, H
    Martinet, O
    Rimoldi, D
    Halkic, N
    Gillet, M
    Chaubert, P
    MacDonald, HR
    Romero, P
    Cerottini, JC
    Speiser, DE
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 174 (03) : 1709 - 1716
  • [3] Butterfield LH, 1999, CANCER RES, V59, P3134
  • [4] Chen Zhi, 2002, Hepatobiliary Pancreat Dis Int, V1, P570
  • [5] Covini G, 1997, HEPATOLOGY, V25, P75
  • [6] Non-immunogenic murine hepatocellular carcinoma Hepa1-6 cells expressing the membrane form of macrophage colony stimulating factor are rejected in vivo and lead to CD8+ T-Cell immunity against the parental tumor
    Dan, QH
    Sanchez, R
    Delgado, C
    Wepsic, HT
    Morgan, K
    Chen, YJ
    Jeffes, EWB
    Lowell, CA
    Morgan, TR
    Jadus, MR
    [J]. MOLECULAR THERAPY, 2001, 4 (05) : 427 - 437
  • [7] Darlington G J, 1987, Methods Enzymol, V151, P19, DOI 10.1016/S0076-6879(87)51006-0
  • [8] De Silva AD, 1999, J IMMUNOL, V163, P4413
  • [9] EFFECT OF SPECIFIC IMMUNOTHERAPY WITH PRE-IMMUNIZATION AGAINST ALPHA-FETOPROTEIN ON A MOUSE TRANSPLANTABLE HEPATOMA
    ENGVALL, E
    PIHKO, H
    JALANKO, H
    RUOSLAHTI, E
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1977, 59 (01) : 277 - 280
  • [10] Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes in human hepatocellular cancer
    Friedl, J
    Stift, A
    Paolini, P
    Roth, E
    Steger, GG
    Mader, R
    Jakesz, R
    Gnant, MFX
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2000, 15 (05) : 477 - 486